MA26514A1 - Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant. - Google Patents
Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.Info
- Publication number
- MA26514A1 MA26514A1 MA25129A MA25129A MA26514A1 MA 26514 A1 MA26514 A1 MA 26514A1 MA 25129 A MA25129 A MA 25129A MA 25129 A MA25129 A MA 25129A MA 26514 A1 MA26514 A1 MA 26514A1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- prostaglandin agonists
- prostaglandin
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5057597P | 1997-06-23 | 1997-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26514A1 true MA26514A1 (fr) | 2004-12-20 |
Family
ID=21966050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA25129A MA26514A1 (fr) | 1997-06-23 | 1998-06-22 | Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6531485B2 (fr) |
AP (1) | AP9801269A0 (fr) |
AR (1) | AR013118A1 (fr) |
AU (1) | AU7349298A (fr) |
CO (1) | CO5080735A1 (fr) |
GT (1) | GT199800083A (fr) |
HR (1) | HRP980356A2 (fr) |
MA (1) | MA26514A1 (fr) |
PA (1) | PA8452701A1 (fr) |
TN (1) | TNSN98104A1 (fr) |
WO (1) | WO1998058911A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0200258A2 (hu) | 1999-03-05 | 2002-05-29 | The Procter & Gamble Co. | C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
DK1132086T3 (da) | 2000-01-31 | 2006-08-28 | Pfizer Prod Inc | Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US7670821B2 (en) * | 2002-05-29 | 2010-03-02 | Dsm Ip Assets B.V. | Method for the purification of microbial protease |
JP2006021998A (ja) * | 2002-07-18 | 2006-01-26 | Ono Pharmaceut Co Ltd | Ep2アゴニストを有効成分とする月経困難症治療剤 |
EP1563846B1 (fr) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Promoteurs de production de facteurs de reparation endogenes |
EP2422814A1 (fr) | 2003-07-25 | 2012-02-29 | Ono Pharmaceutical Co., Ltd. | Remède pour maladies associées aux cartilages |
US7858650B2 (en) | 2004-10-22 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Medicinal composition for inhalation |
US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
US7635716B2 (en) | 2005-01-14 | 2009-12-22 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
CA2610692C (fr) | 2005-06-03 | 2014-11-25 | Ono Pharmaceutical Co., Ltd. | Agent de regeneration et/ou de protection des nerfs |
GB0518494D0 (en) * | 2005-09-09 | 2005-10-19 | Argenta Discovery Ltd | Thiazole compounds |
US7323591B2 (en) | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
AU2007261034B2 (en) * | 2006-06-20 | 2012-09-13 | Allergan, Inc. | Therapeutic compounds |
WO2008008701A2 (fr) * | 2006-07-10 | 2008-01-17 | Allergan, Inc. | Composés thérapeutiques |
AU2007272617B2 (en) * | 2006-07-11 | 2012-11-01 | Allergan, Inc. | Cyclopentane derivatives as antiglaucoma agents |
NZ582705A (en) * | 2007-07-03 | 2012-06-29 | Allergan Inc | Therapeutic substituted cyclopentanes for reducing intraocular pressure |
US7737140B2 (en) * | 2008-04-24 | 2010-06-15 | Allergan, Inc. | Therapeutic compounds |
WO2009137412A1 (fr) * | 2008-05-09 | 2009-11-12 | Allergan, Inc. | Composés thérapeutiques |
WO2009140205A2 (fr) | 2008-05-15 | 2009-11-19 | Allergan, Inc. | Cyclopentanes substitués à visée thérapeutique |
ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
WO2015056504A1 (fr) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | Greffe d'endoprothèse à élution de médicament |
JP7256332B2 (ja) * | 2020-04-21 | 2023-04-11 | クミアイ化学工業株式会社 | メタン生成阻害剤組成物及びメタン生成の抑制方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3888905A (en) * | 1969-02-17 | 1975-06-10 | Searle & Co | Prostaglandin intermediates and optically active isomers thereof |
US3980700A (en) * | 1971-10-07 | 1976-09-14 | G. D. Searle & Co. | Prostaglandin intermediates and optically active isomers thereof |
DE2434133A1 (de) * | 1974-07-12 | 1976-01-22 | Schering Ag | Neue prostansaeurederivate und verfahren zu ihrer herstellung |
GB1521688A (en) * | 1974-11-01 | 1978-08-16 | May & Baker Ltd | Cyclopentane derivatives |
US3932389A (en) | 1974-12-11 | 1976-01-13 | Pfizer Inc. | 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins |
US4197407A (en) | 1977-03-30 | 1980-04-08 | American Cyanamid Company | Prostenoic acids and esters |
US4097601A (en) | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1998
- 1998-06-04 AU AU73492/98A patent/AU7349298A/en not_active Abandoned
- 1998-06-04 US US09/446,099 patent/US6531485B2/en not_active Expired - Fee Related
- 1998-06-04 WO PCT/IB1998/000866 patent/WO1998058911A2/fr active Application Filing
- 1998-06-08 PA PA19988452701A patent/PA8452701A1/es unknown
- 1998-06-18 GT GT199800083A patent/GT199800083A/es unknown
- 1998-06-18 AP APAP/P/1998/001269A patent/AP9801269A0/en unknown
- 1998-06-22 TN TNTNSN98104A patent/TNSN98104A1/fr unknown
- 1998-06-22 MA MA25129A patent/MA26514A1/fr unknown
- 1998-06-22 AR ARP980102993A patent/AR013118A1/es not_active Application Discontinuation
- 1998-06-23 HR HR60/050,575A patent/HRP980356A2/hr not_active Application Discontinuation
- 1998-06-23 CO CO98035644A patent/CO5080735A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US6531485B2 (en) | 2003-03-11 |
HRP980356A2 (en) | 1999-02-28 |
US20030008895A1 (en) | 2003-01-09 |
TNSN98104A1 (fr) | 2005-03-15 |
CO5080735A1 (es) | 2001-09-25 |
AR013118A1 (es) | 2000-12-13 |
GT199800083A (es) | 1999-12-10 |
WO1998058911A2 (fr) | 1998-12-30 |
AU7349298A (en) | 1999-01-04 |
WO1998058911A3 (fr) | 1999-03-18 |
PA8452701A1 (es) | 2000-05-24 |
AP9801269A0 (en) | 1999-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26551A1 (fr) | Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26514A1 (fr) | Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26424A1 (fr) | Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
FR2780057B1 (fr) | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26499A1 (fr) | Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant . | |
MA26468A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26432A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
DZ2890A1 (fr) | 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
MA26687A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26622A1 (fr) | Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26508A1 (fr) | Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation. | |
MA26630A1 (fr) | 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26558A1 (fr) | Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26479A1 (fr) | Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA24529A1 (fr) | Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant . | |
MA26505A1 (fr) | Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26490A1 (fr) | Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant. | |
DZ2188A1 (fr) | Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant. | |
MA26707A1 (fr) | Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26624A1 (fr) | Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26519A1 (fr) | Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
DZ2414A1 (fr) | 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant. |